Lisa H Butterfield

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Immunotherapy of hepatocellular carcinoma
    Lisa H Butterfield
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, CA 90095, USA
    Expert Opin Biol Ther 2:123-33. 2002
  2. ncbi Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy
    Antoni Ribas
    Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California, USA
    J Immunother (1997) 27:354-67. 2004
  3. ncbi Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells
    Jennifer A Wargo
    Department of Surgery, Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Cancer Gene Ther 12:516-27. 2005
  4. ncbi Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, CA 90095, USA
    J Immunol 172:4762-9. 2004
  5. ncbi Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses
    Lana Schumacher
    Division of Surgical Oncology, UCLA Medical Center, University of California Los Angeles, USA
    J Immunother (1997) 27:191-200. 2004
  6. ncbi Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma
    Lisa H Butterfield
    Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA
    Clin Cancer Res 9:998-1008. 2003
  7. ncbi Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells
    Yu-Pei Liao
    Department of Radiation Oncology, Division of Surgical Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Immunol 173:2462-9. 2004
  8. ncbi Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma
    Lynn K Gordon
    Department of Ophthalmology, and the Jules Stein Eye Institute, and the UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 100 Stein Plaza, Los Angeles, CA 90095-7000, USA
    Control Clin Trials 25:400-7. 2004
  9. ncbi T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer
    Lisa H Butterfield
    Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 9:5902-8. 2003
  10. ncbi Determinant spreading and tumor responses after peptide-based cancer immunotherapy
    Antoni Ribas
    Department of Medicine, 54 140 CHS, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Trends Immunol 24:58-61. 2003

Detail Information

Publications33

  1. ncbi Immunotherapy of hepatocellular carcinoma
    Lisa H Butterfield
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, CA 90095, USA
    Expert Opin Biol Ther 2:123-33. 2002
    ..The most recent data supporting the use of immunotherapy for hepatocellular cancer is reviewed in detail...
  2. ncbi Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy
    Antoni Ribas
    Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California, USA
    J Immunother (1997) 27:354-67. 2004
    ..Sequential CTLA4 blockade may enhance the immune activity of DC-based immunotherapy...
  3. ncbi Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells
    Jennifer A Wargo
    Department of Surgery, Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Cancer Gene Ther 12:516-27. 2005
    ..In conclusion, protective immunity after tumor antigen gene-modified DC immunization requires collaboration between CD4+ and CD8+ T cells and NK cells...
  4. ncbi Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, CA 90095, USA
    J Immunol 172:4762-9. 2004
    ..Elucidation of the signaling events that activate these effective cytotoxic cells and the putative suppressive mechanisms in a wild-type environment may provide means to enhance the clinical activity of DC-based approaches...
  5. ncbi Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses
    Lana Schumacher
    Division of Surgical Oncology, UCLA Medical Center, University of California Los Angeles, USA
    J Immunother (1997) 27:191-200. 2004
    ..This study has important implications for the design of DC-based clinical trials...
  6. ncbi Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma
    Lisa H Butterfield
    Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA
    Clin Cancer Res 9:998-1008. 2003
    ....
  7. ncbi Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells
    Yu-Pei Liao
    Department of Radiation Oncology, Division of Surgical Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Immunol 173:2462-9. 2004
    ..1/K(b) transgenic mice. Taken together, these results suggest that radiation modulates MHC class I-mediated antitumor immunity by functionally affecting DC Ag presentation pathways...
  8. ncbi Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma
    Lynn K Gordon
    Department of Ophthalmology, and the Jules Stein Eye Institute, and the UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 100 Stein Plaza, Los Angeles, CA 90095-7000, USA
    Control Clin Trials 25:400-7. 2004
    ..Therefore, surveillance of the eye and vision should be considered in melanoma immunotherapy trials...
  9. ncbi T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer
    Lisa H Butterfield
    Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 9:5902-8. 2003
    ..We wished to test the hypothesis that AFP peptide-reactive T cells could be expanded in vivo in HCC patients immunized with these four AFP peptides...
  10. ncbi Determinant spreading and tumor responses after peptide-based cancer immunotherapy
    Antoni Ribas
    Department of Medicine, 54 140 CHS, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Trends Immunol 24:58-61. 2003
    ....
  11. ncbi Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines
    Antoni Ribas
    Department of Surgery, University of California at Los Angeles, 90095-1782, USA
    Cancer Gene Ther 9:875-83. 2002
    ..In conclusion, in this animal model, IL-12 production by gene-modified DC leads to a cytokine-induced dose-dependent inhibition of antigen-specific antitumor protection...
  12. ncbi Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
    Pawel Kalinski
    Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
    Immunol Res 50:235-47. 2011
    ....
  13. ncbi Current developments in cancer vaccines and cellular immunotherapy
    Antoni Ribas
    Division of Hematology Oncology, Department of Medicine, University of California Los Angeles, 90095 1782, USA
    J Clin Oncol 21:2415-32. 2003
    ....
  14. ncbi Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study
    Jennifer L Steel
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    J Pain Symptom Manage 39:859-71. 2010
    ..The study of symptom clusters is gaining increased attention in the field of oncology in an attempt to improve the quality of life of patients diagnosed with cancer...
  15. ncbi Zinc in innate and adaptive tumor immunity
    Erica John
    Department of Surgery, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    J Transl Med 8:118. 2010
    ..Based on this novel synthesis, approaches which locally regulate zinc levels to promote survival of immune cells and/or induce tumor apoptosis are in order...
  16. ncbi Cancer immunotherapy using gene-modified dendritic cells
    Antoni Ribas
    Departments of Surgery, Medicine, Division of Hematology Oncology, 11 934 Factor Bldg UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Curr Gene Ther 2:57-78. 2002
    ..These data may help in the translation of this promising approach to the clinic...
  17. ncbi Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro
    Shikhar Mehrotra
    Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut 06030, USA
    Cancer Res 63:5607-14. 2003
    ..These observations, therefore, have implications on the DC-based cancer vaccine designs and are relevant in the inquiry into the role of DCs on tolerance induction...
  18. ncbi Melanoma cancer vaccines and anti-tumor T cell responses
    Lazar Vujanovic
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania 15213, USA
    J Cell Biochem 102:301-10. 2007
    ....
  19. ncbi Development of a potency assay for human dendritic cells: IL-12p70 production
    Lisa H Butterfield
    Department of Medicine, Surgery and Immunology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunother 31:89-100. 2008
    ..It defines the stability of DC vaccines. It's application to DC assessments in several on-going early-phase clinical trials is expected to provide data defining the assay value in predicting in vivo efficacy of DC-based vaccines...
  20. ncbi Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer
    Viktoria N Evdokimova
    University of Pittsburgh, Hillman Cancer Center, Department of Medicine, Hematology Oncology, Research Pavilion, Room 1 32, 5117 Centre Avenue, Pittsburgh, PA 15213, USA
    Expert Opin Biol Ther 8:325-36. 2008
    ..Hepatocellular carcinoma (HCC) is a leading cause of cancer death, with few treatment options for advanced disease...
  21. ncbi Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma
    Lisa H Butterfield
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunother 31:294-309. 2008
    ..Responses in CD8+ and CD4+ T cells to additional antigens were noted in 2 patients. The AdVMART1-transduced DC vaccine was safe and immunogenic in patients with metastatic melanoma...
  22. ncbi Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer
    Lisa H Butterfield
    Department of Medicine, Surgery and Immunology University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Cancer Immunol Immunother 56:1931-43. 2007
    ....
  23. ncbi AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients
    Viktoria N Evdokimova
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunother 30:425-37. 2007
    ..Importantly, CD4 T-cell cytokine expression profiles were skewed towards interleukin-2 and interferon-gamma production when activated by adenovirally engineered DC, which has therapeutic implications for vaccination efforts...
  24. ncbi Immunotherapeutic strategies for hepatocellular carcinoma
    Lisa H Butterfield
    Departments of Medicine, Surgery and Immunology, University of Pittsburgh, Hillman Cancer Center, Research Pavilion, Room 1 19, 5117 Centre Avenue, Pittsburgh, Pennsylvania 15213, USA
    Gastroenterology 127:S232-41. 2004
    ..These trials, testing novel immune-based interventions in HCC subjects, have resulted in immunologic responses and have impacted recurrence and survival in HCC subjects...
  25. ncbi Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells
    Shikhar Mehrotra
    Department of Medicine, University of Connecticut School of Medicine, Farmington Avenue, Farmington, CT, USA
    Immunology 113:472-81. 2004
    ..These data suggest that although DCs generated in the presence of IL-10 tend to be non-immunogenic, they are capable of processing and presenting an antigen when the antigen is synthesized within the DC...
  26. ncbi A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides
    Lisa H Butterfield
    Department of Medicine, Surgery and Immunology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 12:2817-25. 2006
    ..We conclude that the human T cell repertoire is capable of responding to the AFP self antigen after the administration of AFP peptide-pulsed DC even in an environment of high circulating levels of this oncofetal antigen...
  27. ncbi Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer
    Yang Liu
    Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunol 177:712-21. 2006
    ..These subdominant epitope-specific T cells can also recognize tumor cells and may be important therapeutically...
  28. ncbi Recent advances in immunotherapy for hepatocellular cancer
    Lisa H Butterfield
    Department of Medicine, Universtiy of Pittsburgh, Medical School, Pittsburgh, USA
    Swiss Med Wkly 137:83-90. 2007
    ..These trials, testing novel immune-based interventions in HCC subjects, have resulted in immunological responses and some have impacted recurrence and survival of HCC subjects...
  29. ncbi Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma
    Ryo Ueda
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    J Transl Med 5:68. 2007
    ..In this report, we characterized GAA-specific CD8+ T cells and innate immune cells in a patient who has survived with anaplastic astrocytoma (AA) for over 12 years without recurrence...
  30. ncbi Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas
    Hideho Okada
    Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Transl Med 5:67. 2007
    ..The prognosis for malignant gliomas remains dismal. We addressed the safety, feasibility and preliminary clinical activity of the vaccinations using autologous glioma cells and interleukin (IL)-4 gene transfected fibroblasts...
  31. ncbi Next generation of immunotherapy for melanoma
    John M Kirkwood
    Hillman Cancer Center, Research Pavilion, Suite 1 32, 5117 Centre Ave, Pittsburgh, PA 15213 2584, USA
    J Clin Oncol 26:3445-55. 2008
    ..Immunotherapy has a long history with striking but limited success in patients with melanoma. To date, interleukin-2 and interferon-alfa2b are the only approved immunotherapeutic agents for melanoma in the United States...
  32. ncbi Rational design of peptide-based tumor vaccines
    Wilson S Meng
    Division of Pharmaceutical Sciences, Duquesne University, Mylan School of Pharmacy, Pittsburgh, Pennsylvania 15282, USA
    Pharm Res 19:926-32. 2002
    ..This review will discuss the basic and clinical aspects of modifying native TAA peptides as tumor vaccines...
  33. ncbi Activation of antigen-presenting cells by DNA delivery vectors
    Wilson S Meng
    Duquesne University, Division of Pharmaceutical Sciences, 600 Forbes Ave, Pittsburgh, PA 15282, USA
    Expert Opin Biol Ther 5:1019-28. 2005
    ..This paper will summarise recent reports of adjuvant properties of viral and non-viral delivery systems...